Aminomethylbenzoic acid (Acidum aminomethylbenzoicum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Coagulants (including clotting factors), hemostatics

Included in the formulation
  • Amben
    solution w / m in / in 
    FARMZASCHITA NPC, GP     Russia
  • Pamba
    solution w / m in / in 
    PROFIT FARM, LLC     Russia
    • АТХ:

    B.02.A.A.03   Aminomethylbenzoic acid

    Pharmacodynamics:

    Inhibition of tissue activators that convert profibrinolysin (plasminogen) to fibrinolysin (plasmin); a direct inhibitory effect on fibrinolysin (to a lesser extent). Promoting the stabilization of fibrin and its deposition in the vascular bed.

    Pharmacological effects

    Hemostatic: hemostatic agent for topical application.

    Pharmacokinetics:

    TCmax immediately after intravenous administration, the therapeutic concentration is maintained up to 3 hours. Elimination by the kidneys is 60-80% unchanged.

    Indications:

    Bleeding during surgical interventions and pathological conditions accompanied by increased fibrinolytic activity of the blood (for neurosurgical, intracavitary, thoracic, gynecological and urological operations, including prostate, lung, pancreas, tonsillectomy, after dental interventions, in operations with AIC) .

    Uterine bleeding, obstetrics, delayed involution of the uterus, medical abortion, manual removal of the placenta, premature detachment of the placenta, intrauterine fetal death, embolism with amniotic fluid.

    Bleeding during burns, shock conditions of various genesis, sepsis, leukemia, acute pancreatitis, metastases in the stomach, liver diseases, peptic ulcer of the stomach and duodenum. No studies of antifibrinolytic amino acids have been found to treat bleeding from the upper gastrointestinal tract in liver diseases and concomitant blood clotting disorders.

    Hemorrhagic conditions caused by radiation sickness; hypocoagulation (hemophilia, Verlhof disease, Willebrand-Jurgens syndrome), bleeding in the hypocoagulant phase of the DIC syndrome, hemorrhagic vasculitis (thrombocytopenia).

    An overdose of anticoagulants or fibrinolytic agents (streptokinase, urokinase), transfusion complications and other conditions accompanied by activation of fibrinolysis; etiotropic therapy of influenza.

    Nasal, gingival and other external bleeding in patients with thrombocytopenic purpura, leukemia, hemorrhagic thrombocytopathy, Rundu-Seder disease, liver cirrhosis, chronic nephritis (with topical application).

    Capillary and parenchymal hemorrhages, bleeding from bones, muscles and other tissues, in cavities and on the surface of the body,including local increase in fibrinolytic activity of the blood and general fibrinolysis arising during various surgical operations, as a means for local stopping (with topical application).


    ICD-10

    XVIII.R50-R69.R58   Bleeding, not elsewhere classified

    XIX.T80-T88.T81.0   Bleeding and hematoma complicating the procedure, not elsewhere classified

    Contraindications:

    Hypersensitivity, propensity to thrombosis and thromboembolic diseases, hypercoagulable phase of DVS-syndrome, chronic renal failure, pregnancy (I trimester), breast-feeding.

    Hemorrhage in the vitreous, severe forms of ischemic heart disease and cerebral ischemia.

    Carefully:

    When treating hematuria with aminomethylbenzoic acid, it is necessary to ensure sufficient fluid intake and control diuresis, since blood clots in the urinary tract can form, which can lead to the development of renal colic. AT experimental research shown, that aminomethylbenzoic acid is a compound with low toxicity. There is no teratogenic effect and influence on the reproductive system.

    Pregnancy and lactation:

    Pregnancy

    The category of FDA recommendations is not defined. Adequate and well-controlled studies on humans and animals have not been conducted. Application in the I trimester is contraindicated.

    Lactation

    There is no information on the penetration into breast milk. Due to the excretion of other medicinal products by milk and the potential risk of undesirable effects on the child during treatment with aminomethylbenzoic acid, it is recommended to stop breastfeeding.

    Dosing and Administration:

    In / in struyno 5-10 ml of 1% solution or IM 100 mg (with acute generalized fibrinolytic bleeding). To stop fibrinolysis against the background of streptokinase treatment - 50 mg; with the development of coagulopathy syndrome - 50-100 mg or IM 100 mg, if necessary, repeated administration (not earlier than 4 hours). In acute fibrinolysis, fibrinogen is additionally administered, while controlling the fibrinolytic activity of the blood and the fibrinogen content in it. The maximum single dose of 100 mg (10 ml of 1% solution).

    Inside after eating, without chewing, squeezed liquid, 100 mg 3-4 times a day.

    Locally. From 1/4 of the sponge to 3-4 sponges or more (depending on the degree, nature and place of bleeding).After a quick drying, the pieces of the sponge are pressed down with a gauze ball to the bleeding surface for 3-5 minutes. The sponge can be placed in a gauze pad for a loose tamponade of the cavity. The tampon is removed after 24 hours. If necessary, the entire wound surface is covered with a chopped sponge; spraying with a syringe or spray.

    Use in children

    Efficiency and safety have not been studied.

    Side effects:

    From the cardiovascular system: increase or decrease in blood pressure, tachycardia, orthostatic hypotension (rarely). From the gastrointestinal tract: nausea and vomiting, diarrhea. Dermatological: thrombophlebitis at the injection site, hypersensitivity, allergic reactions. Other: dizziness, renal colic (with the formation of blood clots in the urinary tract), catarrhal phenomena from the upper respiratory tract.

    Overdose:

    Not described. Treatment is symptomatic.

    Interaction:

    Compatible with a solution of dextrose, hydrolysates, anti-shock liquids.

    Special instructions:

    Treatment is carried out under the control of a coagulogram. When treating hematuria, it is necessary to ensure sufficient fluid intake and monitor diuresis.

    When topical application stops capillary and parenchymal hemorrhages (including bleeding associated with local or general fibrinolysis). The porous and rather dense structure of the sponge allows it to be pressed firmly against the wound surface. The sponge left in the wound is completely absorbed. The use of a sponge with bleeding from large vessels is ineffective.

    It is not represented in the United States Pharmacopeia. Little-studied means.

    Instructions
    Up